Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
ConclusionPsychiatric adverse events comprised only 1.2% of the total reports for semaglutide, liraglutide, and tirzepatide. However, the severity and fatal outcomes of some of these reports warrant further investigation.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
More News: Anxiety | Databases & Libraries | Depression | Drugs & Pharmacology | European Medicines Agency (EMA) | Psychiatry | Statistics | Study | Suicide | Victoza | Women